Ophthalmology Deals Up 1100% in 2026 — Here's the Data

Twelve ophthalmology deals closed between March and September 2026, up 1100% from just one deal in the prior six-month window. That is not a typo. After years of ophthalmology being treated as a niche therapeutic area by large pharma BD teams — overshadowed by oncology and immunology megadeals — the space has become one of the most active deal environments in biopharma. The catalyst: a collision of gene therapy maturation, complement biology validation, and Big Pharma pipeline urgency that turned ophthalmology licensing 2026 into a land grab.

The Data — Ophthalmology Deal Activity, Period over Period

This is the sharpest six-month acceleration for any major therapeutic area tracked in our Deal Benchmarks database since we began capturing period-over-period shifts. The base was low — one deal — but the absolute count of 12 deals in six months puts ophthalmology on par with mid-tier oncology subsegments like bladder cancer and head-and-neck oncology in total transaction volume.

What's Driving the Trend

Three forces converged to produce this surge, and they are mutually reinforcing.

1. Gene therapy proof-of-concept in retinal disease is finally bankable. The FDA's receptiveness to AAV-based gene therapies for inherited retinal dystrophies — building on Luxturna's precedent — gave Big Pharma confidence that these programs can clear regulatory hurdles with manageable clinical packages. AbbVie's deal with REGENXBIO and J&J's $130M upfront agreement with MeiraGTx both center on next-generation retinal gene therapy platforms. These are not option deals. The upfront commitments signal conviction, not exploration.

2. Complement-mediated disease is the new frontier in retinal degeneration. The Biogen-Apellis $5.6B deal is the clearest proof point. After Apellis demonstrated the commercial viability of complement C3 inhibition in geographic atrophy with Syfovre, Biogen paid a premium — the largest ophthalmology deal by total value in at least five years — to own that franchise. This deal resets the valuation ceiling for complement assets targeting retinal disease and signals that GA is now viewed as a multi-billion-dollar commercial opportunity, not a speculative bet.

3. Pipeline gaps are forcing Big Pharma's hand. Merck's acquisition of EyeBio and AbbVie's deal with Aldeyra Therapeutics reflect a strategic reality: several large pharma companies have thin or non-existent ophthalmology pipelines heading into the late 2020s, while their anti-VEGF franchises face biosimilar erosion. Regeneron's Eylea biosimilar competition is already reshaping the market. Companies that lack next-generation retinal assets are now competing for a shrinking pool of clinical-stage programs, which is compressing diligence timelines and inflating deal terms.

Notable Deals

The Biogen-Apellis deal dominates on value, but the strategic read is in the pattern across all five transactions. AbbVie appears twice — once as a licensee (REGENXBIO) and once as a licensor (Aldeyra) — suggesting a deliberate portfolio reshaping, not a one-off acquisition. Merck's EyeBio deal marks its re-entry into ophthalmology after a decade of limited presence in the space. J&J's MeiraGTx agreement, with a $130M upfront for gene therapy assets, is notable because it benchmarks the going rate for clinical-stage retinal gene therapy platforms below the stratospheric levels some biotech boards were expecting. That $130M number should calibrate expectations for founders sitting on preclinical or Phase I programs.

The two undisclosed-value deals (REGENXBIO-AbbVie and EyeBio-Merck) are worth watching. Based on comparable transaction benchmarking through Solidus, gene therapy platform deals with clinical data in retinal indications have been landing in the $200M–$500M total deal value range over the past 18 months — though the Apellis outlier at $5.6B skews the average significantly.

What This Means for BD Teams Right Now

If you're a biotech with retinal assets, this is a seller's market — but it won't last forever. The ophthalmology deal trends 2026 reflect a supply-demand imbalance: more pharma buyers than quality assets. Clinical-stage programs in geographic atrophy, diabetic retinal disease, and inherited retinal dystrophies are commanding premium terms. If you have Phase II data in any of these areas, your inbound interest has likely tripled in the past six months. Use it. Run competitive processes. Do not sign exclusive diligence agreements without significant upfront commitments.

If you're a pharma BD team, speed matters more than precision right now. The MeiraGTx deal closed in April. The Apellis deal closed in June. AbbVie executed two deals within 10 weeks. Diligence cycles in ophthalmology are compressing from 6–9 months to 3–4 months. If your internal governance requires four committee reviews before you can issue a term sheet, you will lose assets to competitors who move faster. Consider pre-positioning — build your target shortlists now and conduct shadow diligence before assets formally come to market.

Deal structures are shifting toward higher upfront commitments. The Apellis deal was structured as a full-value upfront acquisition ($5.6B). MeiraGTx received $130M upfront with no disclosed milestones. This pattern suggests that licensors in ophthalmology are increasingly rejecting milestone-heavy, backend-loaded structures. BD teams offering 10–15% of total deal value as upfront payments will find themselves outbid. The market is moving toward 40–60% upfront for clinical-stage assets, based on recent benchmarking data from our Deal Benchmarks platform.

Watch the gene therapy manufacturing angle. Two of the five notable deals involve AAV-based gene therapies. Manufacturing capacity for retinal gene therapies remains constrained, and programs with CMC de-risked — meaning they have scalable manufacturing processes and established CDMO relationships — will command premiums. If you are a biotech founder, investing in manufacturing readiness is not a nice-to-have; it is a deal value driver worth $20M–$50M in upfront premium based on recent comparables.

Benchmark your deal against current market rates using the Ambrosia calculator. Ophthalmology deal terms are moving fast — what was market-rate in Q1 2026 is already below market in Q3.